95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
Eun Seop Seo1,2†
In Hwa Jeong3,4†Hee Young Ju1Ju Kyung Hyun1Ji Won Lee1Keon Hee Yoo1Won Young Heo3Ki Woong Sung1Hee Won Cho1*Eun-Suk Kang3*- 1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- 2Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea
- 3Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
- 4Department of Laboratory Medicine, Dong-A University Hospital, Dong-A University College of Medicine, Busan, Republic of Korea
By Seo ES, Jeong IH, Ju HY, Hyun JK, Lee JW, Yoo KH, Heo WY, Sung KW, Cho HW and Kang E-S (2025) Front. Immunol. 16:1517387. doi: 10.3389/fimmu.2025.1517387
In the published article, there was an error in the Funding statement. The original funding statement is as follows: “The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT) (2017R1A2B4008178). Additionally, this research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HA15C0007).”
The correct Funding statement appears below.
“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the National Research Foundation of Korea (NRF) grant, funded by the Korean government (MSIT) (2017R1A2B4008178, 2022R1F1A1075238). Additionally, this research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health and Welfare, Republic of Korea (grant number: HA15C0007).”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: neuroblastoma, PIRCHE, haploidentical hematopoietic stem cell transplantation, relapse/refractory, HLA mismatch
Citation: Seo ES, Jeong IH, Ju HY, Hyun JK, Lee JW, Yoo KH, Heo WY, Sung KW, Cho HW and Kang E-S (2025) Corrigendum: Predicted indirectly recognizable HLA epitopes scores and clinical outcomes after haploidentical stem cell transplantation in pediatric patients with relapsed neuroblastoma. Front. Immunol. 16:1565304. doi: 10.3389/fimmu.2025.1565304
Received: 23 January 2025; Accepted: 24 January 2025;
Published: 04 February 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Seo, Jeong, Ju, Hyun, Lee, Yoo, Heo, Sung, Cho and Kang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hee Won Cho, aHc4Ny5jaG9Ac2Ftc3VuZy5jb20=; Eun-Suk Kang, ZXNrYW5nQHNra3UuZWR1
†These authors have contributed equally to this work and share first authorship